Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
8(72.7%)
Phase 2
3(27.3%)
11Total
Phase 1(8)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT06475495Phase 1Active Not Recruiting

Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis

Role: collaborator

NCT06138132Phase 1Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Role: collaborator

NCT06152172Phase 1Active Not Recruiting

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

Role: collaborator

NCT07403188Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Role: lead

NCT06193889Phase 2Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Role: lead

NCT06451159Phase 1Active Not Recruiting

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Role: collaborator

NCT06588491Phase 2Active Not Recruiting

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

Role: lead

NCT05938725Phase 1Active Not Recruiting

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Role: lead

NCT06342960Phase 1Active Not Recruiting

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Role: lead

NCT06400303Phase 1Active Not Recruiting

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Role: lead

NCT06384976Phase 2Active Not Recruiting

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Role: lead

NCT06590545Phase 1Not Yet Recruiting

Anti-CD 19 CAR-T Cell Therapy in Patients with ANCA Vasculitis

Role: collaborator

All 12 trials loaded